Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Breast 7CNS 6Sarcoma 4Gynecologic 4Genitourinary 4Gastrointestinal 4Tumor-Agnostic 3Thoracic 2Plasma cell 2Other hematologic neoplasm 2Other 2NET 1Myeloid 1Lymphoid 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Weight Loss 1Thrombocytopenia 1Splenomegaly 1Multiple Myeloma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Fever 1Fatigue 1Anemia 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Quality of Life × Other hematologic neoplasm × Clear all
NCT04870320 2022-04-08

Study of Attention and Memory Treatments for Cancer Survivors

University of California, San Francisco

Phase NA Completed
49 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT02948283 2021-02-12

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

City of Hope Medical Center

Phase 1 Completed
3 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Lymphadenopathy, Anemia, Fatigue, Fever, Lymphocytosis, Multiple Myeloma, Splenomegaly, Thrombocytopenia, Weight Loss, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡